RT Journal Article
SR Electronic
A1 Helwick, Caroline
T1 Sequential Therapy with Gefitinib for Advanced Non-Small Cell Lung Cancer
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 4
SP 13
OP 14
DO 10.1177/155989770800800410
UL http://mdc.sagepub.com/content/8/4/13.2.abstract
AB In previous studies, gefitinib combined with chemotherapy has provided no survival gain compared with chemotherapy alone for patients with advanced non-small cell lung cancer (NSCLC). However, a phase 3 trial has shown that sequential therapy with gefitinib may offer clinical benefit after platinum-based doublet chemotherapy in this setting. The West Japan Thoracic Oncology Group trial [WJTOG 0203; NCT00144066] involved patients who were randomly assigned to 3–6 cycles of chemotherapy alone (298 patients) or to 3 cycles of chemotherapy followed by daily gefitinib until disease progression (300 patients).